Iovance Biotherapeutics, Inc. (IOVA)
Automate Your Wheel Strategy on IOVA
With Tiblio's Option Bot, you can configure your own wheel strategy including IOVA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IOVA
- Rev/Share 0.6587
- Book/Share 2.3783
- PB 1.2278
- Debt/Equity 0.07
- CurrentRatio 4.1783
- ROIC -0.4632
- MktCap 975087280.0
- FreeCF/Share -1.0763
- PFCF -2.806
- PE -2.5116
- Debt/Assets 0.0556
- DivYield 0
- ROE -0.4971
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | IOVA | Goldman | Neutral | Sell | -- | $1 | July 15, 2025 |
| Downgrade | IOVA | UBS | Buy | Neutral | -- | $2 | May 16, 2025 |
| Downgrade | IOVA | Truist | Buy | Hold | -- | -- | May 12, 2025 |
| Downgrade | IOVA | Citizens JMP | Mkt Outperform | Market Perform | -- | -- | May 9, 2025 |
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
Published: June 27, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit - IOVA
Published: June 27, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 27, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Iovance investors who were adversely affected by alleged securities fraud between May 9, 2024 and May 8, 2025.
Read More
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit
Published: June 25, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 25, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025, both dates inclusive (the "Class Period"), of the important July 14, 2025 lead plaintiff deadline. So What: If you purchased Iovance securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
Published: June 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Iovance To Contact Him Directly To Discuss Their Options
Read More
Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure– Hagens Berman
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, June 23, 2025 (GLOBE NEWSWIRE) -- Biotechnology firm Iovance Biotherapeutics Inc. (NASDAQ: IOVA) announced a significant leadership transition, confirming the resignation of Chief Financial Officer Jean-Marc Bellemin, effective July 10, 2025. Mr. Bellemin, who assumed the CFO role in November 2020, is reportedly departing to pursue other endeavors, according to a regulatory filing. Bellemin's exit comes at a tumultuous time, as the company is grappling with a recent commercial setback for its flagship drug, Amtagvi, and the specter of a class-action securities lawsuit.
Read More
ROSEN, LEADING INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) between May 9, 2024 and May 8, 2025, both dates inclusive (the “Class Period”), of the important July 14, 2025 lead plaintiff deadline.
Read More
Deadline Alert: Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, June 23, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming July 14, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025, inclusive (the “Class Period”).
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
Iovance Biotherapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - IOVA
Published: June 23, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 23, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). Shareholders who purchased shares of IOVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: June 20, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , June 20, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) have opportunity to lead the securities fraud class action lawsuit.
Read More
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA
Published: June 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) between May 9, 2024 and May 8, 2025, both dates inclusive (the “Class Period”), of the important July 14, 2025 lead plaintiff deadline.
Read More
Faruqi & Faruqi Reminds Iovance Biotherapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 14, 2025 - IOVA
Published: June 20, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Iovance To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Iovance between August 8, 2024 and May 8, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , June 20, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Iovance Biotherapeutics, Inc. ("Iovance" …
Read More
IOVA COURT REMINDER: Iovance Biotherapeutics, Inc. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)
Published: June 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit.
Read More
Contact The Gross Law Firm by July 14, 2025 Deadline to Join Class Action Against Iovance Biotherapeutics, Inc.(IOVA)
Published: June 19, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 19, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). Shareholders who purchased shares of IOVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure – Hagens Berman
Published: June 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, June 18, 2025 (GLOBE NEWSWIRE) -- Biotechnology firm Iovance Biotherapeutics Inc. (NASDAQ: IOVA) announced a significant leadership transition, confirming the resignation of Chief Financial Officer Jean-Marc Bellemin, effective July 10, 2025. Mr. Bellemin, who assumed the CFO role in November 2020, is reportedly departing to pursue other endeavors, according to a regulatory filing. Bellemin's exit comes at a tumultuous time, as the company is grappling with a recent commercial setback for its flagship drug, Amtagvi, and the specter of a class-action securities lawsuit.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA
Published: June 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
ROSEN, A LEADING LAW FIRM, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA
Published: June 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) between May 9, 2024 and May 8, 2025, both dates inclusive (the “Class Period”), of the important July 14, 2025 lead plaintiff deadline.
Read More
IOVA LAWSUIT ALERT: Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. Investors - Lead Plaintiff Deadline July 14, 2025
Published: June 17, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 17, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=153457&wire=1&utm_campaign=7 or contact Joseph E. Levi, Esq.
Read More
IOVA SHAREHOLDER ALERT: BFA Law Reminds Iovance Biotherapeutics, Inc. Investors of Upcoming July 14 Class Action Deadline - Contact the Firm if You Suffered Losses
Published: June 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit.
Read More
Iovance Biotherapeutics, Inc. (IOVA) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before July 14, 2025
Published: June 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 16, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=153351&wire=1&utm_campaign=4 or contact Joseph E. Levi, Esq.
Read More
Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. (IOVA) Shareholders of Class Action Lawsuit and July 14, 2025 Deadline
Published: June 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 16, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=153343&wire=1&utm_campaign=15 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
Published: June 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ:IOVA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Join Class Action to Recover Losses from Iovance Biotherapeutics, Inc. (IOVA) - Contact Levi & Korsinsky Before July 14, 2025
Published: June 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 16, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=153333&wire=1&utm_campaign=31 or contact Joseph E. Levi, Esq.
Read More
IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV
Published: June 16, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , June 16, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ: IOVA) for violations of the federal securities laws. Shareholders who purchased the Company's securities between May 9, 2024 and May 8, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before July 14, 2025.
Read More
Investors in Iovance Biotherapeutics, Inc. (IOVA): Protect Your Rights - Contact Levi & Korsinsky Before July 14, 2025
Published: June 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 16, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=153303&wire=1&utm_campaign=11 or contact Joseph E. Levi, Esq.
Read More
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: June 16, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , June 16, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ: IOVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 9, 2024 and May 8, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before July 14, 2025.
Read More
Class Action Lawsuit Filed: Iovance Biotherapeutics, Inc. (IOVA) - Join by July 14, 2025 - Contact Levi & Korsinsky
Published: June 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 16, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=153262&wire=1&utm_campaign=8 or contact Joseph E. Levi, Esq.
Read More
IOVA CLASS ACTION NOTICE: Iovance Biotherapeutics, Inc. Was Sued For Securities Fraud; Contact BFA Law if You Suffered Losses
Published: June 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit.
Read More
Class Action Lawsuit Filed: Iovance Biotherapeutics, Inc. (IOVA) - Join by July 14, 2025 - Contact Levi & Korsinsky
Published: June 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 13, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=153045&wire=1&utm_campaign=8 or contact Joseph E. Levi, Esq.
Read More
Investors who lost money on Iovance Biotherapeutics, Inc. (IOVA) should contact Levi & Korsinsky about pending Class Action - IOVA
Published: June 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) of a class action securities lawsuit.
Read More
About Iovance Biotherapeutics, Inc. (IOVA)
- IPO Date 2010-10-15
- Website https://www.iovance.com
- Industry Biotechnology
- CEO Frederick G. Vogt
- Employees 838